Dx Focus: Clinical and Regulatory PCR and Nucleic Acid Testing News
April 14, 2011
Dx Focus: Clinical and Regulatory PCR and Nucleic Acid Testing News
FDA approves Cepheid's Xpert C. difficile/Epi test.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Quidel Obtains CE Mark for AmpliVue C. Difficile, Company's First Handheld MDx Test
March 29, 2012 / PCR Insider - Cepheid's Q1 Revenues Grow on Strong Clinical Reagent Sales; Analysts 'Unconcerned' with Net Loss
April 26, 2012 / PCR Insider - Cepheid Highlights Strong Uptake of Xpert CT/NG as Q1 Revenues Rise 19 Percent
April 25, 2013 / PCR Insider - On Heels of FDA Approval, Cepheid's Xpert CT/NG Test Performs Well in Multi-Center Clinical Study
March 14, 2013 / PCR Insider - Cepheid Reports Q4, FY '12 Revenue Growth, but Looks to Address Issues from 'Challenging' Year
January 31, 2013 / PCR Insider